Search
Menu
Hamamatsu Corp. - Earth Innovations LB 2/24

Irreproducible research spurs reassessment of editorial guidelines

Facebook X LinkedIn Email
Jul. 8, 2013 — Publish or perish, they say. But what if the pressure to do so is undermining the scientific process? C. Glenn Begley, senior vice-president at TetraLogic Pharmaceuticals in Malvern, Pa., is acutely aware of this possibility. Whenever he asks professors what’s the most important thing for students and postdoctoral fellows to do while at their institution. The answer, almost invariably, is to get a paper into Nature or Science or Cell. Doing so guarantees the next position for the student or postdoc, and the next grant for the principal investigator. This of course leads to...Read full article

Related content from Photonics Media



    Articles


    Webinars


    Photonics Dictionary Terms


    Media
    Published: July 2013
    Astra ZenecaBayer HealthcareC. Glenn BegleyDifferent WavelengthsGary BoasGary Boas BlogIrreproducible researchLee EllisNatureNovartisSix red flags for suspect workTetraLogic Pharmaceuticals

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.